The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …

New insights have emerged from maturing long-term academic and commercial clinical
trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of …

Chronic myelogenous leukemia (CML) in children is relatively rare. Because of a lack of
robust clinical study evidence, management of CML in children is not standardized and often …

While type I interferon (IFN) is best known for its key role against viral infection, accumulating
preclinical and clinical data indicate that robust type I IFN production in the tumor …

The first clinical trials of the safety and efficacy of interferon-alpha2 (IFN-alpha2) were
performed about 30 years ago. Since then, several single-arm studies have convincingly …

SARS-CoV-2 is the viral agent responsible for the pandemic that in the first months of 2020
caused about 400,000 deaths. Among compounds proposed to fight the SARS-CoV-2 …

Cancer stem cells (CSC s) generate transient‐amplifying cells and thereby contribute to
cancer propagation. A fuller understanding of the biological features of CSC s is expected to …

The management of chronic myeloid leukemia (CML) diagnosed during pregnancy is a rare
and challenging situation. We report the treatment and outcome of 87 cases diagnosed in …

Abstract Purpose of Review Tyrosine kinase inhibitors (TKIs) are very successful for the
treatment of chronic myeloid leukaemia (CML) but are not curative in most patients due to …

The tyrosine kinase inhibitor Imatinib Mesylate has dramatically improved the clinical
outcome of chronic myeloid leukemia (CML) patients in the chronic phase of the disease …